このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Fibrodysplasia Ossificans Progressiva (FOP) 接続レジストリ

2026年11月9日 更新者:The International FOP Association

FOP 接続: Fibrodysplasia Ossificans Progressiva コミュニティのグローバル レジストリ

The Fibrodysplasia Ossificans Progressiva (FOP) Registry is a global, non-interventional, voluntary database that captures demographic and disease data directly from FOP patients and their caregivers via a secure, web-based patient portal. A physician portal (in development) will allow physicians to enter clinical data about their patients. The objectives are to organize the international FOP community for participation in clinical trials; to enable FOP patients worldwide to report data in a shared forum; to improve the collective understanding of FOP natural history; and to advance the understanding of FOP treatment outcomes.

調査の概要

状態

募集

条件

詳細な説明

The FOP Registry is a global, non-interventional, voluntary database that captures demographic and disease data directly from FOP patients and their caregivers via a secure, web-based patient portal. No experimental intervention is involved. The objectives are to organize the international FOP community for participation in clinical trials; to enable FOP patients worldwide to report data in a shared forum; to improve the collective understanding of FOP natural history; and to advance the understanding of FOP treatment outcomes.

The Registry collects data through two sources. First, the Patient Portal (launched in July 2015) allows FOP patients and caregivers to enter information about their experiences living with FOP. Second, the Physician Portal (in development) will allow physicians to enter clinical data about patients under their care. The Registry will be capable of including data on specific marketed therapies under the direction and control of a sponsoring pharmaceutical company. Key identifiers will link the physician-reported data with the Patient Portal data.

Participants must have a confirmed diagnosis of FOP and the participant (or a parent or legal guardian) must be willing and able to provide written informed consent. There are no exclusion criteria. Data collected in the Patient Portal include: patient demographics and diagnosis pathway; medical and dental care; clinical research participation and biospecimen donation; heterotopic ossification (bone growth and episodic flare-ups); other signs and symptoms by body system; patient-reported outcomes (physical functioning, pain, fatigue, and general health); and assistive devices, aids, attendants, and adaptations. Because the Registry is designed to accommodate participants along a broad spectrum of FOP disease severity, most of the data fields are optional, allowing participants a high degree of flexibility in how much information they contribute, which also minimizes participant burden.

After completing the informed consent, participants enter their baseline (historical) data. Participants will be encouraged to update their information at least twice per year. Participants may withdraw their consent at any time without prejudice or providing an explanation. The Registry has no pre-specified end date and will continue for as long as it is sustainable and useful to the FOP community.

研究の種類

観察的

入学 (推定)

800

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Missouri
      • North Kansas City、Missouri、アメリカ、064116
        • 募集
        • The International Fibrodysplasia Ossificans Progressiva Association (IFOPA)
        • コンタクト:
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

確率サンプル

調査対象母集団

Individuals with Fibrodysplasia Ossificans Progressive (FOP) from the international FOP community will be invited to join the Registry.

説明

Inclusion Criteria:

  • Participants must have a confirmed diagnosis of FOP.
  • Participants (or a parent or legal guardian) must be willing and able to provide written informed consent.

Exclusion Criteria:

  • There are no exclusion criteria.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:OTHER
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
FOP Patients

None. IFOPA-REG-001 is a FOP patient observational registry study.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Patient Reported Changes in New Bone Growth Using a Patient-Directed Survey Developed by the IFOPA
時間枠:Baseline, then every six months for up to 10 years

The patient is able to report changes in new bone growth among 27 joints and body locations.

Baseline, then every six months for up to 10 years
Patient Reported Changes in Episodic Flare-Ups Using a Patient-Directed Survey Developed by the IFOPA
時間枠:Baseline, then every six months for up to 10 years

The patient is able to report changes in episodic flare-ups among 27 joints and body locations.

Baseline, then every six months for up to 10 years
Patient Reported Changes in Mobility Using a Patient-Directed Survey Developed by the IFOPA
時間枠:Baseline, then every six months for up to 10 years

The patient is able to report changes in mobility among 27 joints and body locations.

Baseline, then every six months for up to 10 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Patient Reported Changes in Health Resource Utilization Using a Patient-Directed Survey Developed by the IFOPA
時間枠:Baseline, then every six months for up to 10 years

The number of visits to a Physician and a Dentist, as well as the number of hospitalizations and reasons for the hospitalizations, are used to assess health resource utilization.

Baseline, then every six months for up to 10 years
Patient Reported Changes in Signs Related to the Ear Using a Patient-Directed Survey Developed by the IFOPA
時間枠:Baseline, then every six months for up to 10 years

The patient is able to report new or continuing health issues related to the ears.

Baseline, then every six months for up to 10 years
Patient Reported Changes in Signs Related to the Skin Using a Patient-Directed Survey Developed by the IFOPA
時間枠:Baseline, then every six months for up to 10 years

The patient is able to report new or continuing health issues related to the skin.

Baseline, then every six months for up to 10 years
Patient Reported Changes in Signs Related to the Central Nervous System Using a Patient-Directed Survey Developed by the IFOPA
時間枠:Baseline, then every six months for up to 10 years

The patient is able to report new or continuing health issues related to the central nervous system.

Baseline, then every six months for up to 10 years
Patient Reported Changes in Signs Related to the Pulmonary System Using a Patient-Directed Survey Developed by the IFOPA
時間枠:Baseline, then every six months for up to 10 years

The patient is able to report new or continuing health issues related to the pulmonary system.

Baseline, then every six months for up to 10 years
Patient Reported Changes in Signs Related to the Gastrointestinal System Using a Patient-Directed Survey Developed by the IFOPA
時間枠:Baseline, then every six months for up to 10 years

The patient is able to report new or continuing health issues related to the gastrointestinal system.

Baseline, then every six months for up to 10 years
Patient Reported Changes in Signs Related to the Cardiovascular System Using a Patient-Directed Survey Developed by the IFOPA
時間枠:Baseline, then every six months for up to 10 years

The patient is able to report new or continuing health issues related to the cardiovascular system.

Baseline, then every six months for up to 10 years
Patient Reported Changes in Signs Related to the Renal System Using a Patient-Directed Survey Developed by the IFOPA
時間枠:Baseline, then every six months for up to 10 years

The patient is able to report new or continuing health issues related to the renal system.

Baseline, then every six months for up to 10 years
Patient Reported Changes in Signs Related to the Endocrine System Using a Patient-Directed Survey Developed by the IFOPA
時間枠:Baseline, then every six months for up to 10 years

The patient is able to report new or continuing health issues related to the endocrine system.

Baseline, then every six months for up to 10 years

その他の成果指標

結果測定
メジャーの説明
時間枠
FOP-身体機能アンケート(PFQ)を使用して患者が報告した日常生活動作の変化
時間枠:ベースライン、その後 6 か月ごとに最大 10 年間
ベースライン、その後 6 か月ごとに最大 10 年間
PROMIS Global Health Scaleを使用して患者が全体的な健康状態の変化を報告
時間枠:ベースライン、その後 6 か月ごとに最大 10 年間
ベースライン、その後 6 か月ごとに最大 10 年間
Patient Reported Changes in the Need for Assistive Devices, Aids, Attendants, and Adaptations Using a Survey Developed by the IFOPA
時間枠:Baseline, then every six months for up to 10 years

The patient is able to respond Yes or No to questions related to his/her need for Assistive Devices, Aids, Attendants, and Adaptations as a result of his/her FOP disease.

Baseline, then every six months for up to 10 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Mark Hamilton, PhD、International Fibrodysplasia Ossificans Progressiva Association

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2015年7月1日

一次修了 (推定)

2035年7月31日

研究の完了 (推定)

2040年12月31日

試験登録日

最初に提出

2016年3月6日

QC基準を満たした最初の提出物

2016年4月15日

最初の投稿 (推定)

2016年4月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Formal data sharing agreements are planned between the International FOP Association and biopharmaceutical companies doing research in Fibrodysplasia Ossificans Progressiva (FOP). Publications are also planned with biopharmaceutical companies and physician researchers.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。